Burton Christensen, Ph.D.
Former Executive Vice President, Research, Theravance, Inc

Eugene Shakhnovich, Ph.D.
Co-founder, Professor of Chemistry, Harvard University

Scientific Advisory Board, Observer

Tim Mattson, PhD.
Industry Manager, Life Sciences, Intel Corporation

Burton Christensen, Ph.D.. Former Executive Vice President, Research, Theravance, Inc. (formerly Advanced Medicine, Inc.) In addition to VITAE PHARMACEUTICALS, Inc., Dr. Christensen serves as a consultant to Theravance, Inc. and Essential Therapeutics, Inc. Dr. Christensen spent the majority of his career at Merck Research Laboratories, where he held various positions before retiring in 1992 as a Senior Vice President. Among his honors are the sixth Cecil L. Brown lectureship, the Thomas Alva Edison Patent Award, the Merck Directors Scientific Award, and the Chemical Pioneer Award. Dr. Christensen serves on the editorial boards of Journal of Antibiotics and Synlett. Dr. Christensen holds a Ph.D. and an A.M. degree in chemistry from Harvard University and a B.S. degree in chemistry from Iowa State University.

Eugene Shakhnovich, Ph.D., Co-founder and Professor of Chemistry, Harvard University. Dr. Shakhnovich received his M.S. in 1981 in Theoretical Physics from Moscow University. In 1984, he received his Ph.D. in Theoretical Biophysics and Molecular Biology in from the Russian Academy of Sciences. He was a Research Fellow and Senior Research Fellow in the Institute of Protein Research of the then Soviet Academy of Sciences until his arrival to Harvard in 1990, where he held Assistant (1991) and Associate (1995) Professorships. He is now Full Professor of Chemistry, Chemical Biology and Biophysics (since 1997) at Harvard. His research interests include theoretical studies of Protein Folding, Evolution and Design, Rational Drug Design, theory of Complex systems, Bioinformatics and Theoretical Material Science. He is the author of more than 200 publications and a recipient of several awards and fellowships. In 1997, he founded Initio, a company based on SMoG technology. In 2001, Initio merged with VITAE PHARMACEUTICALS.

Tim Mattson, Ph.D., Industry Manager, Life Sciences, Intel Corporation. Dr. Mattson is Intel's worldwide industry segment manager for life sciences. He is responsible for Intel's strategy for the life sciences market and is Intel's chief spokesman to the life sciences community. This was followed by a Post-doc at Caltech where he ported his molecular scattering software to the Caltech/JPL hypercubes. Since then, he has held a number of commercial and academic positions with computational science on high performance computers as the common thread.

Dr. Mattson joined Intel in 1993 to work on a variety of parallel computing problems. This included benchmarking, system performance modeling, and applications research with an emphasis on molecular dynamics and quantum chemistry. He was a senior scientist on Intel's ASCI teraFLOPS project: a project that resulted in the first computer to run MPLINPACK in excess of one teraFLOPS.

Cluster computing has been an important part of Dr. Mattson's work since the late 1980's. At Intel, he has played a leadership role in guiding Intel's strategies in this market. He is a founder of Open Cluster Group; the group responsible for OSCAR, the most popular package in the world for building HPC clusters.

Tim Mattson earned a PhD. in Chemistry for his work on quantum molecular scattering theory (UCSC, 1985).

[back to top]